Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned

Lancet Infect Dis. 2019 Jan;19(1):3-4. doi: 10.1016/S1473-3099(18)30549-8. Epub 2018 Nov 23.

Authors

Jan-Willem C Alffenaar¹, Simon Tiberi², Giovanni Battista Migliori³

Affiliations

¹ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands. Electronic address: j.w.c.alffenaar@umcg.nl.
² Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK; Division of Infection, The Royal London Hospital, Barts Health NHS Trust, London, UK.
³ (4) Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.

PMID: 30477962
DOI: 10.1016/S1473-3099(18)30549-8

No abstract available

Publication types

Comment

MeSH terms

Ethambutol*
Humans
Linezolid
Models, Biological
Prospective Studies
Research Design
Tuberculosis, Pulmonary*

Substances

Ethambutol
Linezolid